Fallout at Meridian Health Systems

Instructions

This simulation is inspired by real-world events and will unfold over three steps. At each stage, you should select all of the responses that you feel are appropriate given the information you have received up to that moment. After each submission, your selections will be checked and the scoring rationale for each choice will be provided.

To get started, please enter your email:

Reexamining Innovation Oversight and Scientific Governance

Meridian Health Systems, a high-profile healthtech company, is in crisis after serious doubts have emerged about the efficacy of its breakthrough blood-testing device. A whistleblower from within the company’s research unit revealed that clinical accuracy results were selectively reported, and that regulatory filings were incomplete or misleading.

The board had enthusiastically endorsed the CEO-founder’s vision and fast-tracked market expansion after being told that the device had “FDA alignment.” However, no independent review of clinical results was ever commissioned. The board’s Technology and Growth Committee had oversight of product milestones but did not include directors with clinical or regulatory expertise. Now, regulatory scrutiny looms, and the board must act decisively.

What should the board do at this point?

A. Commission an independent validation of Meridian’s core technology and regulatory claims

B. Request the CEO to present original clinical data and correspondence with regulators

C. Suspend further marketing of the blood-testing device pending board review

D. Form a science and ethics advisory group to report directly to the full board

E. Publicly affirm the board’s confidence in the CEO’s integrity and leadership

F. Review whistleblower disclosures and reporting protocols through the audit committee

G. Place the Chief Medical Officer and head of R&D on immediate leave

H. Convene an executive session of independent directors to reflect on governance blind spots

Choice	Rationale	Answer
A	Ensures objective scientific review and signals board accountability.	✅
B	Appropriate as part of the record but insufficient for independent validation.	❌
C	Board should not direct operational decisions; should focus on oversight and accountability.	❌
D	Adds clinical rigor and improves board readiness for future oversight.	✅
E	Premature endorsements may erode stakeholder trust and impair board independence.	❌
F	Reinforces governance of ethics, compliance, and whistleblower processes.	✅
G	Personnel actions should be based on findings, not optics.	❌
H	Provides a space for candid board reflection on oversight failures.	✅

Rebuilding Trust Amid Investor and Media Scrutiny

With mounting press attention and growing skepticism among investors, Meridian’s board is under pressure to explain its oversight of clinical validation and regulatory compliance. Investor groups are questioning how the board allowed such a major product to scale without direct independent review. Social media commentators have framed the story as “Theranos 2.0,” and congressional staffers are reportedly preparing inquiries.

Regulatory agencies have not yet announced formal investigations, but the damage to reputation is growing by the day. The board must determine how to engage stakeholders without compromising legal risk or undermining investigative processes underway.

What should the board do now?

A. Appoint a board-designated director with healthcare expertise to serve as external spokesperson

B. Release a public statement acknowledging the board’s commitment to independent product review

C. Postpone any all-staff employee events until Meridian completes its internal investigation

D. Host a virtual town hall with institutional investors to address governance reforms

E. Retain a crisis communications firm with expertise in healthcare reputation management

F. Publish a letter from the CEO highlighting the company’s long-term innovation roadmap

G. Invite an external regulatory consultant to brief the board on expected agency actions

Choice	Rationale	Answer
A	Strengthens communication credibility and aligns with best practices.	✅
B	Signals transparency and acknowledges governance accountability.	✅
C	Preventing employee gatherings could be seen as evasive.	❌
D	Engages key stakeholders constructively and improves trust.	✅
E	Helps shape narrative while respecting boundaries of legal review.	✅
F	Reinforcing CEO messaging may appear tone-deaf during trust crisis.	❌
G	Equips board with literacy for informed oversight of the process.	✅

Strengthening Long-Term Oversight of Regulated Innovation

As investigations and audits begin, Meridian’s board recognizes the need to address deeper structural issues. Directors acknowledge they did not adequately challenge optimistic performance claims and were overly reliant on the CEO’s narrative. Some directors lacked experience with regulated clinical products, and committee charters failed to define clear oversight pathways for scientific risk.

The board now seeks to institutionalize new governance practices to prevent such lapses in the future and build a framework for ongoing oversight of innovation with public health implications.

What should the board do now?

A. Create a standing board committee focused on innovation and regulatory ethics

B. Require board-level review of all clinical products prior to market launch

C. Incorporate scientific governance literacy into annual director education

D. Develop a protocol for commissioning independent validation of high-risk claims

E. Limit CEO media appearances until investigations conclude

F. Require all future board members have regulatory expertise

G. Initiate quarterly reporting to the full board on compliance and product safety

H. Delegate scientific oversight solely to the audit committee

Fallout at Meridian Health Systems

Instructions

Reexamining Innovation Oversight and Scientific Governance

Answer Key

Rebuilding Trust Amid Investor and Media Scrutiny

Answer Key

Strengthening Long-Term Oversight of Regulated Innovation

Answer Key

Leave a Reply Cancel reply

Choice	Rationale	Answer
A	Institutionalizes structured oversight for future innovation risks.	✅
B	Management should have ultimate accountability for product integrity.	❌
C	Strengthens board capacity and director effectiveness.	✅
D	Ensures high-risk product claims are independently scrutinized.	✅
E	Operational execution; board may set tone but should not micromanage.	❌
F	Over emphasizing one type of expertise could impact overall bench strength.	❌
G	Supports continuous board engagement on compliance matters.	✅
H	Oversight of science and product integrity requires broader board involvement.	❌

Fallout at Meridian Health Systems

Instructions

Reexamining Innovation Oversight and Scientific Governance

Answer Key

Rebuilding Trust Amid Investor and Media Scrutiny

Answer Key

Strengthening Long-Term Oversight of Regulated Innovation

Answer Key

Leave a Reply Cancel reply

More Filters

Thank you for browsing our resources.